1. Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) 
Martin C. Michel, Christopher R. Chapple 
European Urology 
Volume 49, Issue 3, Pages (March 2006)
DOI: /j.eururo
Copyright © 2006 Elsevier B.V. Terms and Conditions

2. Fig. 1
(A) Change from preinfusion in diastolic blood pressure (DBP) following infusion of phenylephrine at 2h after the dosing of placebo, tamsulosin OCAS 0.4mg and alfuzosin XL 10mg. (B) Change from preinfusion in total peripheral resistance (TPR) following infusion of phenylephrine at 2h after the dosing of placebo, tamsulosin OCAS 0.4mg and alfuzosin XL 10mg.
European Urology  , DOI: ( /j.eururo )
Copyright © 2006 Elsevier B.V. Terms and Conditions

3. Fig. 2
(A) Percentage change from baseline in Imaxact based on the change from preinfusion in diastolic blood pressure. Data are least square means±95%CI. (B) Percentage change from baseline in Imaxact based on the change from preinfusion in total peripheral resistance. Data are least square means±95%CI.
European Urology  , DOI: ( /j.eururo )
Copyright © 2006 Elsevier B.V. Terms and Conditions

4. Fig. 3
Proportion of positive orthostatic tests (OTs) following dosing of tamsulosin OCAS 0.4mg and alfuzosin XL 10mg in elderly volunteers.
European Urology  , DOI: ( /j.eururo )
Copyright © 2006 Elsevier B.V. Terms and Conditions

5. Fig. 4
Proportion of discordant pairs showing a positive orthostatic test comparing treatment of elderly volunteers with tamsulosin OCAS 0.4mg and alfuzosin XL 10mg; ns, not significant.
European Urology  , DOI: ( /j.eururo )
Copyright © 2006 Elsevier B.V. Terms and Conditions

6. Fig. 5
Effect on vital signs on postural change following dosing with either tamsulosin OCAS 0.4mg or alfuzosin XL 10mg; (A) systolic blood pressure (SBP); (B) diastolic blood pressure (DBP). *p<0.05.
European Urology  , DOI: ( /j.eururo )
Copyright © 2006 Elsevier B.V. Terms and Conditions